https://ir.acadia-pharm.com/news-re...armaceuticals-and-stoke-therapeutics-announce
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program
– Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undisclosed neurodevelopmental target
– Combines Stoke’s TANGO research platform with Acadia’s expertise in neurology drug development and commercialization
– Stoke receives a $60 million upfront payment and potential milestone payments of up to $907 million and royalties on future sales
ACADIA PARTNERSHIP STOKE THERAPEUTICS
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.48 |
Change
0.160(1.04%) |
Mkt cap ! $1.978B | |||
| Open | High | Low | Value | Volume |
| $15.10 | $15.48 | $15.04 | $6.154M | 402.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1498 | $15.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 8296 | 2 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |